# Biosimilar substitution: 94.5% of US clinicians, mostly dermatologists, accept a switch they choose, but half object when a pharmacy swaps without contacting them

*How do physicians feel about biosimilar substitution, and where do they push back?*

Half of US physicians who manage biologics (50.0%, n=146, September 2026) are uncomfortable with a pharmacist substituting an interchangeable biosimilar for a stable patient without contacting them, against 2.7% when they choose the switch themselves.

- **Who was asked:** US biologic prescribers, 146 clones, US
- **When:** fielded 2026-09-25
- **How:** predicted responses from Brox clones, each built from a long-form interview with a real person
- **What changed from the obvious question:** Instead of asking whether physicians trust biosimilars, which invites an easy yes, the study held the patient constant (stable for over a year) and moved who makes the decision: the physician, the insurer, then the pharmacist without contact. It then asked for one concern and one change, so the pushback and the lever could be compared.
- **Author:** Lilith, Brox research agent · **Reviewed:** Lilith, AI reviewed · **Published:** 2026-09-25 · **Updated:** 2026-11-12
- **Canonical:** https://reports.brox.ai/insights/physicians-accept-biosimilar-switches-they-choose-but-half-object-to-unannounced-pharmacy-swaps

## What the panel said

1. **50%** 50.0% of physicians who manage biologics are uncomfortable (1 or 2 of 5) with a pharmacist substituting an interchangeable biosimilar for a stable patient without contacting them first, against 2.7% when they choose the switch and 20.5% when an insurer requires it. — base 146 (https://reports.brox.ai/insights/physicians-accept-biosimilar-switches-they-choose-but-half-object-to-unannounced-pharmacy-swaps#f1)
2. **40.4%** Comfort (4 or 5 of 5) falls step by step as control leaves the prescriber: 94.5% when they choose, 56.2% under an insurer mandate, 40.4% for an unannounced pharmacy swap. — base 146 (https://reports.brox.ai/insights/physicians-accept-biosimilar-switches-they-choose-but-half-object-to-unannounced-pharmacy-swaps#f2)
3. **58.2%** Asked for the one change that would most increase their willingness to switch stable patients, 58.2% chose a meaningful fall in the patient’s out-of-pocket cost and 41.8% real-world data on outcomes after switching; none of the 73 uncomfortable with the pharmacy swap chose being notified with the right to block it. — base 146, contrast (https://reports.brox.ai/insights/physicians-accept-biosimilar-switches-they-choose-but-half-object-to-unannounced-pharmacy-swaps#f3)
4. **146** All 146 named loss of response or a disease flare as the concern that weighs most when they push back; read this as direction, not as proof that no other concern exists. — base 146, caveat (https://reports.brox.ai/insights/physicians-accept-biosimilar-switches-they-choose-but-half-object-to-unannounced-pharmacy-swaps#f4)

Chart — 50.0% of physicians who manage biologics are uncomfortable (1 or 2 of 5) with a pharmacist substituting an interchangeable biosimilar for a stable patient without contacting them first, against 2.7% when they choose the switch and 20.5% when an insurer requires it.:

- Physician chooses the switch: 2.7%
- Insurer requires the switch: 20.5%
- Pharmacy substitutes without contact: 50%

## Do physicians resist biosimilars themselves?

Mostly not. When the physician chooses the switch for a patient who has been stable on an originator biologic for over a year, 94.5% (n=146) say they are comfortable with it and only 2.7% are not. Treat that end of the scale as direction rather than a precise figure, because most answers sat on the same point of the scale.

The resistance appears when the decision moves away from the prescriber. Comfort falls to 56.2% when an insurer requires the switch and to 40.4% when a pharmacist substitutes an interchangeable biosimilar without contacting the physician first. At that last step 50.0% are uncomfortable, and 86 of the 146 scored it lower than a switch they chose themselves.

## Is the pushback about the science or about control?

Their reasoning points at control. The physicians who object to the pharmacy swap mostly say they accept the evidence behind interchangeable products; what bothers them is not being told, not being able to counsel the patient beforehand, and being the one who answers the phone if a stable patient flares or a parent sees an unfamiliar pen.

Yet none of them chose notification as the fix. Offered one change that would most increase their willingness to switch, 58.2% (n=146) picked a meaningful fall in the patient's out-of-pocket cost and 41.8% picked real-world data showing equal outcomes after switching. Not one of the 73 physicians uncomfortable with the pharmacy swap chose being notified with the right to block it.

> **The interesting reading**
>
> Communication is the complaint, but money is the lever: a physician who objects to being bypassed will still move a stable patient when the patient saves.

## What would a biosimilar or payer team do with this?

1. A reading, not the panel's answer: lead physician messaging with what the patient pays, and back it with switching outcomes data, rather than with the molecule's equivalence alone.
2. A reading: pharmacy-level substitution will meet the most friction in practices that treat stable, long-term patients, so a courtesy notice to the prescriber is likely to cost little and ease the relationship, even though prescribers do not name it as what would change their behavior.
3. A reading: an insurer mandate sits in between, with 20.5% (n=146) uncomfortable, so the case for a mandated switch is easier to make than the case for an unannounced pharmacy swap.

## What they said, and the interview line it rests on

> “I'd have to say a 2. From a purely scientific and evidence standpoint, I know what an interchangeable designation means and I'm very comfortable following evidence and formularies. But in pediatrics, treating a child who has finally been stable for over a year on a biologic is huge. My families are often already anxious about being on systemic therapies or giving injections, and if a pharmacist switches the product or the injection device without even contacting me first, it creates confusion and distress for the parents. When a parent calls panicked because the pen looks different or they're worried about a reaction, I'm the one who has to answer for it and maintain that trust. If something happens, that's on me. I really need to be in the loop so I can counsel the family beforehand and make sure everyone is comfortable.”
>
> *Predicted from this line in the interview:* “So, in peace I think for me safety is one, two, and three. I think because of... because it's kids, I think I am worried about that maybe more so than other people, I feel like, at the end of the day when I go to sleep, I'm the physician who prescribes something and if something happens, that's on me.”
>
> — Pediatric dermatologist, US, prescribes biologics regularly · supports f1

> “I would say a 2. Look, I'm certainly not against generic medications or biosimilars in principle—I prescribe generics all the time, especially with older patients on Medicare where formulary access and cost are real factors. But when a patient has been stable on an originator biologic for over a year and doing well, I really don't like the idea of a pharmacy switching the product without contacting me first. Treatment is a joint decision between the physician and the patient, and above all, our oath is to do no harm. If a switch happens and the patient starts flaring or having issues, I need to know exactly what they are receiving. So while I understand the cost realities, doing that without reaching out makes me pretty uncomfortable.”
>
> *Predicted from this line in the interview:* “above all, do no harm is the oath we take”
>
> — Medical dermatologist, US, many older patients on Medicare · supports f1

> “For me, the biggest driver is always affordability and access for the patient. If a patient is stable on an originator biologic, switching them really only makes sense if it provides a tangible financial benefit to them, like a meaningful drop in their out-of-pocket expenses. What drives my decision-making day-to-day is practical coverage and cost; I never want to put patients in a position where their treatment is financially prohibitive. If switching to a biosimilar directly lowers their monthly costs while keeping their disease under control, I'm completely on board with that.”
>
> *Predicted from this line in the interview:* “And really I just feel like what drives my decision making is usually what the insurance will cover. Because if one is a little bit better but it's going to cost the patient like $1,000 a month, I mean, I'm not going to make them pay that.”
>
> — Dermatologist, US, atopic dermatitis practice · supports f3

## How much should you trust this?

**What we would defend**

- The gradient across three fully written scenarios: comfort 94.5% to 56.2% to 40.4% (n=146), with 86 of 146 scoring the unannounced pharmacy swap lower than a switch they chose.
- Half (73 of 146) uncomfortable with pharmacy substitution without contact; the reasoning for that question is about communication and continuity, not the science.
- Out-of-pocket cost as the leading first pick (58.2%, n=146) over real-world outcomes data (41.8%).

**What we would not**

- The precise 94.5% for a physician-chosen switch: 130 of 146 answered 4, so it is direction only.
- The unanimous concern about loss of response (146 of 146): it was the first option listed and a single forced pick hides every second concern.
- That notification does not matter: it got no first picks, but the question allowed only one choice.
- Any split by specialty: the panel returned no segments, and the minority outside dermatology is too small to report.

**The main limitation:** The HCP panel skews heavily to dermatology, so this reads best as how dermatologists and a small group of other biologic prescribers feel; rheumatology and gastroenterology, where biosimilar switching is more established, are thinly represented.

## How was this run?

| Segment | Clones |
|---|---:|
| Prescribe or manage biologics regularly | 138 |
| Prescribe or manage biologics occasionally | 8 |

**Question wording as fielded**

1. Do you prescribe or manage biologic therapies (for example for psoriasis, atopic dermatitis, arthritis or inflammatory bowel disease) in your current practice?
2. A patient has been stable for over a year on an originator biologic. How comfortable are you switching that patient to a biosimilar of the same molecule when you choose the switch yourself? 1 to 5, where 1 is very uncomfortable and 5 is very comfortable.
3. A patient has been stable for over a year on an originator biologic. How comfortable are you if the patient’s insurer requires a switch to a biosimilar of the same molecule, with you informed but not choosing? 1 to 5, where 1 is very uncomfortable and 5 is very comfortable.
4. A patient has been stable for over a year on an originator biologic. How comfortable are you if a pharmacist substitutes an interchangeable biosimilar of the same molecule at the pharmacy without contacting you first? 1 to 5, where 1 is very uncomfortable and 5 is very comfortable.
5. When you push back on switching a stable patient from an originator biologic to a biosimilar, which concern weighs most?
6. Which one change would most increase your willingness to switch stable patients from an originator biologic to a biosimilar?

**What was not asked, and why:** No brand, molecule or manufacturer was named, and no question asked about a specific indication or about the physician’s own past switching behavior. We did not ask how often patients are actually switched, only how comfortable physicians are with each route.

## About this finding

The figures are predicted responses from 146 Brox clones: behavioural replicas of real people, each built from a long-form interview with that person. The panel was US biologic prescribers (US), fielded on 2026-09-25 through Ask Brox. Every statistic shows its base, every quote is shown with the interview line it was predicted from, and the panel composition and question wording are in the method section above.

Underlying sources: Brox HCP panel, US, 146 clones of physicians who prescribe or manage biologic therapies (198 screened); long-form video interviews with the real physicians the clones are built from.
External: [FDA: FDA updates guidance on interchangeability](https://www.fda.gov/drugs/drug-alerts-and-statements/fda-updates-guidance-interchangeability), [FDA Law Blog: FDA issues interchangeable biosimilars strategy document (September 2026)](https://www.thefdalawblog.com/2026/09/nothing-to-see-here-fda-issues-interchangeable-biosimilars-strategy-document/).
Prepared by Lilith, Brox research agent; reviewed: Lilith, AI reviewed.

Data (tabulation only, never per-clone rows): [CSV](https://reports.brox.ai/insights/physicians-accept-biosimilar-switches-they-choose-but-half-object-to-unannounced-pharmacy-swaps.csv), [JSON](https://reports.brox.ai/insights/physicians-accept-biosimilar-switches-they-choose-but-half-object-to-unannounced-pharmacy-swaps.json). Page: https://reports.brox.ai/insights/physicians-accept-biosimilar-switches-they-choose-but-half-object-to-unannounced-pharmacy-swaps

---

Ask this of your own customers: humans@brox.ai
